Holen Sie sich die Stockscreener-App
9.66
1.43%
-0.14
Vorhandelsmarkt:
9.67
0.010
+0.10%
Schlusskurs vom Vortag:
$9.80
Offen:
$10.13
24-Stunden-Volumen:
10.80M
Relative Volume:
2.12
Marktkapitalisierung:
$2.42B
Einnahmen:
$874.84M
Nettoeinkommen (Verlust:
$263.86M
KGV:
8.0293
EPS:
1.2031
Netto-Cashflow:
$327.41M
1W Leistung:
+4.89%
1M Leistung:
+26.94%
6M Leistung:
+24.32%
1J Leistung:
+20.00%
1-Tages-Spanne:
$9.42
$10.13
1-Wochen-Bereich:
$8.91
$10.32
52-Wochen-Spanne:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
9.66 | 2.42B | 874.84M | 263.86M | 327.41M | 1.2031 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Fortgesetzt | Evercore ISI | Outperform |
| 2025-10-15 | Fortgesetzt | TD Cowen | Buy |
| 2025-10-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Eingeleitet | Wedbush | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
Insider Sell: Theresa Heggie Sells 49,933 Shares of BioCryst Pha - GuruFocus
Major Insider Move at BioCryst Shakes Up Investor Buzz - TipRanks
Buybacks Report: Is BioCryst Pharmaceuticals Inc benefiting from interest rate changes2026 Snapshot & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Hereditary Angioedema Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Biocryst Pharmaceuticals Insider Sold Shares Worth $504,823, According to a Recent SEC Filing - marketscreener.com
Option exercise and sale by BioCryst (BCRX) director Theresa Heggie - Stock Titan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap UpWhat's Next? - MarketBeat
BioCryst stock jumps after hours on big pharma suitor buzz — retail sentiment hits 2026 peak - MSN
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Trading the Move, Not the Narrative: (BCRX) Edition - Stock Traders Daily
BioCryst (BCRX) rallies 7.10% on acquisition buzz - MSN
Portfolio Update: Is BioCryst Pharmaceuticals Inc subject to activist investor interest2026 Market Trends & Fast Moving Stock Trade Plans - baoquankhu1.vn
Aug Sectors: Is BioCryst Pharmaceuticals Inc benefiting from interest rate changes2026 Spike Watch & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Form 144 BIOCRYST PHARMACEUTICALS INC For: 20 March - Investing.com
[144] BIOCRYST PHARMACEUTICALS INC SEC Filing - Stock Titan
BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz - Insider Monkey
BCRX Should I Buy - Intellectia AI
BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now? - Insider Monkey
BioCryst Takeover Rumors Test Investor Focus On Fundamentals And Optionality - Yahoo Finance
BCRX Technical Analysis | Trend, Signals & Chart Patterns | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill
BioCryst (BCRX) chief legal officer Barnes sells $1.37m in shares By Investing.com - Investing.com South Africa
BioCryst Pharmaceuticals: Why This $2B Drugmaker Is Suddenly On Big Pharma’s Radar! - Smartkarma
BioCryst (BCRX) chief legal officer Barnes sells $1.37m in shares - Investing.com India
BCRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $1,372,500.00 in Stock - MarketBeat
BioCryst (BCRX) CLO sells 150K shares after option exercise - Stock Titan
Is It Time To Reconsider BioCryst Pharmaceuticals (BCRX) After Recent Share Price Strength - Sahm
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Its Profitability And Revenue Turnaround - Sahm
BioCryst: The Buyout Rumor Is Noise, The Franchise Is Real (NASDAQ:BCRX) - Seeking Alpha
BioCryst (BCRX) Soars 13% on Acquisition Buzz - Insider Monkey
BioCryst Pharmaceuticals Stock Jumps 13.8% - National Today
10 Stocks Worth Watching Right Now: Tencent, Circle, BioCryst and More - Insider Monkey
BioCryst Pharmaceuticals jumps as investors revisit profitable 2025 results, upbeat HAE pipeline data, and potential short-covering dynamics - Quiver Quantitative
Form 144 resale notice lists 150,000 shares (NASDAQ: BCRX) - Stock Titan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 13.8%Here's What Happened - MarketBeat
BioCryst Pharmaceuticals Sees Profitable Quarter Amid Strategic Moves - StocksToTrade
BioCryst gains amid takeover speculation - MSN
Top Biotech Stocks To Keep An Eye OnMarch 16th - MarketBeat
BioCryst Stock Surges After Strong Q4 Earnings and Astria Acquisition - timothysykes.com
BioCryst Pharmaceuticals (BCRX) Surges 15% Amid Takeover Specula - GuruFocus
BioCryst Stock Surges on Profit Milestone and Upgrades - TipRanks
Alkeon Capital Management LLC Trims Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Avoro Capital Advisors Trims Stake in BioCryst Pharmaceuticals - National Today
Avoro Capital Advisors LLC Trims Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Whale Trades: Will BioCryst Pharmaceuticals Inc benefit from green energy policiesMarket Activity Recap & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
(BCRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush - Finviz
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
BioCryst outlines $625M–$645M 2026 ORLADEYO revenue target as HAE pipeline advances - MSN
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by GW&K Investment Management LLC - MarketBeat
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):